Medicare
Synvisc retains its Medicare code and reimbursement rate
Published in Medical Letter on the CDC and FDA, December 11th, 2005
The U.S. Centers for Medicare and Medicaid Services have decided not to implement an earlier decision that would have placed all viscosupplement products in the same J-Code for billing next year. As a result of this latest decision, Medicare patients will continue to have access to Synvisc and there will be no change to the method by which product reimbursement in the U.S. is determined for 2006.
Genzyme is dedicated to making a major positive impact on...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Antibiotic Resistance
Antimicrobial resistance is common in Shiga toxin-producing E. coli - Breast Cancer Therapy
Desferal inhibits breast tumors and does not interfere with doxorubicin - Pneumococcal Disease
Prevalence of pediatric pneumococcal serotypes is increased in elderly - Staphylococcus Aureus
Community-associated methicillin-resistant Staphylococcus aureus is on the rise - Tuberculosis Diagnosis
C-18-carboxypropylbetaine improves sensitivity of sputum smear microscopy - Acute Myeloid Leukemia
Clofarabine's duration of response improves outcome for elderly AML patients - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
